# Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

> **NCT01722305** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 29 (actual)

## Conditions studied

- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- Central Nervous System Lymphoma
- Intraocular Lymphoma
- Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
- Recurrent Adult Diffuse Large Cell Lymphoma
- Retinal Lymphoma

## Interventions

- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT01722305
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-08
- **Primary completion:** 2016-06-03
- **Final completion:** 2019-07-15
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722305, "Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01722305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*